The fact that the presence of some of frailty criteria (prefrailty) is associated with a reduction in aromatase activity suggests that, as the first-line adjuvant treatment in post-menopausal women with breast cancer, aromatase inhibitor treatments may worsen frailty syndrome in these women. This evidence concerns the gene CYP19A1 and breast cancer.